Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 3/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | FPR3 | P25089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705958 | 0.88 | FPR2 (0.31) | DAGLAFPR2HRH3 | |
| SCHEMBL1707516 | 0.86 | DAGLA (0.41) | DAGLAFPR2HRH3FPR3 | |
| SCHEMBL1705863 | 0.77 | CES1 (0.47) | CES1DAGLAFPR2 | |
| SCHEMBL15931723 | 0.75 | HCAR2 (0.45) | CES1 | |
| SCHEMBL18782175 | 0.72 | HCAR2 (0.42) | CES1 | |
| SCHEMBL1706448 | 0.71 | CES1 (0.39) | CES1DAGLA | |
| SCHEMBL18782173 | 0.69 | CES1 (0.39) | CES1HRH3 | |
| SCHEMBL16011738 | 0.69 | CES1 (0.39) | CES1DAGLAHRH3 | |
| SCHEMBL1705848 | 0.68 | PTGER1 (0.31) | CES1 | |
| SCHEMBL1760523 | 0.68 | HCAR2 (0.39) | CES1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102803237-B | Oxazole and thiazole derivatives as alx receptor agonists | ACTELION PHARMACEUTICALS LTD | 2014-09-24 | — | — | CN | disclosed |
| US-8674111-B2 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-18 | — | — | US | disclosed |
| EP-2440536-B1 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-06 | — | — | EP | disclosed |
| CN-102803237-A | Oxazole and thiazole derivatives as alx receptor agonists | ACTELION PHARMACEUTICALS LTD | 2012-11-28 | — | — | CN | disclosed |
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2440536-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143158-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | P2RX1, GLP1R, P2RX7 | CES1 1393/4885DAGLA 3893/4885FPR2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.